The DOI matches its Crossref record.
The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis: Efficacy of IVIg for TEN
Abstract
BACKGROUND: Quantitative analysis of intravenous immunoglobulin (IVIg) treatment against toxic epidermal necrolysis (TEN) is lacking. OBJECTIVES: To provide a meta-analysis evidence-based examination of IVIg efficacy against TEN. METHODS: A systematic review and meta-analysis of literature published before 31 July 2011 was conducted. In observational controlled studies with at least eight patients with TEN receiving IVIg treatment, a pooled estimate of mortality risk was determined, comparing IVIg and supportive care. Statistical analyses were performed on raw data to compare the clinical differences between (i) high-dose and low-dose IVIg treatment in adult patients and (ii) paediatric and adult patients treated with IVIg. RESULTS: Seventeen studies met inclusion criteria. Overall mortality rate of patients with TEN treated with IVIg was 19.9%. The pooled odds ratio (OR) for mortality from six observational controlled studies comparing IVIg and supportive care was 1.00 [95% confidence interval (CI) 0.58-1.75; P=0.99]. The pooled OR for mortality in patients treated with high-dose IVIg vs. supportive care was 0.63 (95% CI 0.27-1.44; P=0.27). Adults treated with high-dose IVIg exhibited significantly lower mortality than those treated with low-dose IVIg (18.9% vs. 50%, respectively; P=0.022); however, multivariate logistic regression model adjustment indicated that IVIg dose does not correlate with mortality (high vs. low dose: OR 0.494; 95% CI 0.106-2.300; P=0.369). Paediatric patients treated with IVIg had significantly lower mortality than adults (0% vs. 21.6%; P=0.001). CONCLUSIONS: Although high-dose IVIg exhibited a trend towards improved mortality and children treated with IVIg had a good prognosis, the evidence does not support a clinical benefit of IVIg. Randomized controlled trials are necessary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Update on the use of immunoglobulin in human disease: A review of evidence
Perez, E. E., Orange, J. S., Bonilla, F., Chinen, J., Chinn, I. K., Dorsey, M., El-Gamal, Y., Harville, T. O., Hossny, E., Mazer, B., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.09.023 · Cited by 666
Severe cutaneous adverse reactions to drugs
Duong, T. A., Valeyrie-Allanore, L., Wolkenstein, P., & Chosidow, O. (2017) · The Lancet · doi:10.1016/s0140-6736(16)30378-6 · Cited by 445
Schwartz, R. A., McDonough, P. H., & Lee, B. W. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.05.002 · Cited by 338
Zimmermann, S., Sekula, P., Venhoff, M., Motschall, E., Knaus, J., Schumacher, M., & Mockenhaupt, M. (2017) · JAMA Dermatology · doi:10.1001/jamadermatol.2016.5668 · Cited by 328
Creamer, D., Walsh, S. A., Dziewulski, P., Exton, L. S., Lee, H. Y., Dart, J. K. G., Setterfield, J., Bunker, C. B., Ardern‐Jones, M. R., Watson, K. M. T., et al. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14530 · Cited by 277
Metadata
- Authors
- Huang, Y.-C., Li, Y.-C., & Chen, T.-J.
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-07-26
- Volume
- 167
- Issue
- 2
- Pages
- 424-432
- ISSN
- 0007-0963 (ISSN-L)
- OpenAlex
- W1946959996
- Cited by
- 223
- References
- 0
- FWCI
- 2.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis: Efficacy of IVIg for TEN. https://app.cochat.ai/papers/10.1111/j.1365-2133.2012.10965.x
- The paper
- Huang, Y.-C., Li, Y.-C., & Chen, T.-J. (2012). The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis: Efficacy of IVIg for TEN. British Journal of Dermatology. https://doi.org/10.1111/j.1365-2133.2012.10965.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.